Oral Session 1-5A AML: AlloHSCT

[OS1-5A-2] Trends in survival of AML patients undergoing related and unrelated HCT during the past two decades

Masamitsu Yanada¹, Masayoshi Masuko², Jinichi Mori³, Jun Aoki⁴, Shohei Mizuno⁵, Takahiro Fukuda⁶, Kazuhiko Kakihana⁷, Yukiyasu Ozawa⁸, Shuichi Ota⁹, Heiwa Kanamori¹⁰, Takehiko Mori¹¹, Hirohisa Nakamae¹², Tetsuya Eto¹³, Souichi Shiratori¹⁴, Tetsuo Maeda¹⁵, Koji Iwato¹⁶, Tatsuo Ichinohe¹⁷, Yoshinobu Kanda¹⁸, Junji Tanaka¹⁹, Yoshiko Atsuta^20,21, Shingo Yano²² (1.Aichi Cancer Center, Nagoya, 2.Niigata University Medical and Dental Hospital, Niigata,, 3.Jyoban Hospital Tokiwa Foundation, Fukushima, 4.Yokohama City University Medical Center, Yokohama, 5.Aichi Medical University, Nagakute, 6.National Cancer Center Hospital, Tokyo, 7.Tokyo Metropolitan Komagome Hospital, Tokyo, 8.Japanese Red Cross Nagoya First Hospital, Nagoya, 9.Sapporo Hokuyu Hospital, Sapporo, 10.Kanagawa Cancer Center, Yokohama,, 11.Keio University School of Medicine, Tokyo, 12.Osaka City University, Osaka, 13.Hamanomachi Hospital, Fukuoka, 14.Hokkaido University Faculty of Medicine, Sapporo, 15.Osaka University Graduate School of Medicine, Osaka, 16.Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital, Hiroshima, 17.Hiroshima University Hospital, Hiroshima, 18.Jichi Medical University, Shimotsuke, 19.Tokyo Women's Medical University, Tokyo, 20.Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, 21.Nagoya University Graduate School of Medicine, Nagoya, 22.Jikei University School of Medicine, Tokyo)